Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCytosorbents Crp

Cytosorbents Crp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
5.69 USD -0.11 ( 1.90%)
Last update at 2026-11-11T20:22:00Z
VOLUME
21013
Market Cap
19.10M

Momentum Score

…

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.50
Low
5.93
High
52 Week Price Range
0.30
Low
7.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cytosorbents Corporation develops and commercializes hemoadsorption blood‑purification devices intended to remove inflammatory mediators in critically ill and perioperative patients. Long‑term growth drivers include wider clinical adoption across indications, expansion of international distribution and reimbursement, and supporting clinical research that could support broader use. Investors may find the company attractive because it appears positioned in a niche critical‑care therapy area with potential for revenue expansion as procedural uptake increases.
Principal risks are uncertain clinical evidence and regulatory or reimbursement hurdles that could limit adoption, plus the potential need for ongoing financing to fund commercialization and operations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.80
Dividend Yield
-
Revenue TTM
37.22M
Revenue Per Share
11.86
Gross Profit TTM
26.65M
Debt / Equity
4.93
ROE
-336.21%
Net Debt
22.86M
ROCE
-41.30%
Diluted EPS TTM
-5.94

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.60M -22.41M -30.06M -33.91M -25.30M
Net income -8.20M -20.72M -29.25M -32.81M -24.56M
Selling general administrative 35.65M 35.00M 37.87M 37.14M 38.48M
Selling and marketing expenses - - 0.44M - -
Gross profit 26.49M 25.13M 21.95M 15.40M 29.06M
Reconciled depreciation 1.63M 1.74M 2.03M 1.13M 1.13M
Ebit -14.24M -16.79M -29.90M -31.52M -22.75M
Ebitda -12.74M -15.22M -27.88M -29.07M -20.17M
Depreciation and amortization 1.50M 1.57M 2.02M 2.45M 2.58M
Non operating income net other - - - -2.52M -2.58M
Operating income -14.24M -16.79M -31.95M -31.52M -22.75M
Other operating expenses 51.30M 52.38M 63.03M 60.88M 62.85M
Interest expense 2.61M 1.40M 0.16M 0.13M 4.00M
Tax provision -0.40M -1.69M -0.81M -1.09M -0.74M
Interest income - - - 0.13M 0.03M
Net interest income -2.61M -1.40M -0.16M 0.13M 0.03M
Income tax expense -0.40M -1.69M -0.81M -1.09M -0.74M
Total revenue 37.06M 35.59M 31.08M 29.36M 40.11M
Total operating expenses 40.73M 41.91M 53.90M 46.93M 51.81M
Cost of revenue 10.57M 10.47M 9.13M 13.96M 11.05M
Total other income expense net 5.64M -5.62M 1.89M -2.38M -2.55M
Net income from continuing ops -8.20M -20.72M -28.51M -32.81M -24.56M
Net income applicable to common shares - - - -32.81M -24.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 44.18M 47.37M 53.26M 63.23M 89.52M
Intangible assets 3.23M 3.75M 3.91M 4.39M 4.70M
Other current assets 1.55M 8.27M 1.83M 2.49M 2.87M
Total liab 38.28M 36.26M 29.99M 27.86M 26.94M
Total stockholder equity 5.90M 11.11M 23.28M 35.38M 62.58M
Other current liab 6.30M 5.61M 6.49M 6.27M 8.15M
Common stock 0.06M 0.05M 0.05M 0.04M 0.04M
Capital stock 0.06M 0.05M 0.05M 0.04M 0.04M
Retained earnings -312.21M -304.01M -282.51M -254.00M -221.19M
Good will 3.23M - - - -
Other assets - 0.00M - 1.73M 6.65M
Cash 6.25M 3.28M 14.13M 22.14M 52.14M
Total current liabilities 9.71M 9.82M 14.55M 9.71M 13.69M
Current deferred revenue - 0.42M 1.38M 1.68M 2.16M
Net debt 22.86M 23.61M 4.18M -3.89M -38.32M
Short term debt 0.54M 0.45M 2.87M 0.11M 0.57M
Short long term debt - - 2.50M - -
Short long term debt total 29.11M 26.89M 18.31M 18.25M 13.82M
Other stockholder equity 321.02M 310.81M 305.20M 287.00M 283.19M
Property plant equipment - - - 10.74M 18.57M
Total current assets 20.63M 21.60M 25.70M 33.76M 64.30M
Net tangible assets - - - 35.37M 62.58M
Net receivables 7.55M 7.32M 6.06M 5.67M 4.52M
Long term debt 16.67M 14.00M 2.54M 5.00M -
Inventory 5.28M 2.73M 3.68M 3.46M 4.77M
Accounts payable 2.87M 3.34M 3.80M 1.66M 2.81M
Accumulated other comprehensive income -2.98M 4.25M 0.53M 2.33M 0.53M
Common stock total equity - - - 0.04M 0.04M
Retained earnings total equity - - - -254.00M -221.19M
Non currrent assets other 0.05M 1.51M -3.65M 1.73M 1.94M
Non current assets total 23.55M 25.77M 27.56M 29.47M 25.22M
Capital lease obligations 12.44M 12.90M 13.27M 13.25M 13.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.67M -1.01M -6.46M -4.28M
Change to liabilities - - - -3.25M 2.43M
Total cashflows from investing activities -0.41M -0.67M -0.94M -6.46M -4.28M
Net borrowings 2.48M 10.00M 0.00M 5.00M 5.00M
Total cash from financing activities 9.31M 9.33M 14.47M 4.96M 0.72M
Change to operating activities - - - 0.03M 0.15M
Net income -8.20M -20.72M -28.51M -32.81M -24.56M
Change in cash -1.99M -5.85M -8.22M -29.99M -17.60M
Begin period cash flow 9.76M 15.62M 23.83M 53.83M 71.42M
End period cash flow 7.77M 9.76M 15.62M 23.83M 53.83M
Total cash from operating activities -12.38M -14.43M -21.66M -28.23M -14.01M
Issuance of capital stock 5.39M 0.18M 14.26M - -
Depreciation 0.95M 1.75M 2.03M 1.13M 1.13M
Other cashflows from investing activities -0.25M -0.39M -0.40M -0.37M -0.64M
Change to inventory -2.54M 0.50M -0.12M 0.95M -2.35M
Change to account receivables 0.42M -1.72M -0.25M -1.29M 0.42M
Sale purchase of stock - - - -0.04M -0.09M
Other cashflows from financing activities 9.31M -0.85M 0.22M -42494.00M 0.81M
Change to netincome - - - 7.01M 8.78M
Capital expenditures 0.16M 0.28M 0.94M 6.46M 4.28M
Change receivables - - - -1.29M 0.42M
Cash flows other operating - - - 0.03M 0.15M
Exchange rate changes - - - - -0.02M
Cash and cash equivalents changes - - - -29.73M -17.60M
Change in working capital -1.03M -4.38M 2.36M -3.56M 0.64M
Stock based compensation 2.77M 3.76M 3.70M 3.80M 6.20M
Other non cash items -6.87M 5.16M -1.24M 3.21M 2.58M
Free cash flow -12.54M -14.71M -22.59M -34.69M -18.29M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CTSO
Cytosorbents Crp		 -0.11
1.90%		 5.69 - 7.20 0.51 11.43 1.19 -1.92
ABT
Abbott Laboratories		 -1.17
1.06%		 109.29 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.02
0.02%		 101.61 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -5.50
1.70%		 318.79 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.30
0.63%		 48.57 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Cytosorbents Crp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

305 College Road East, Princeton, NJ, United States, 08540

732 329 8885

https://www.cytosorbents.com

129

Name Title Year Born
Dr. Phillip P. Chan M.D., Ph.D. CEO & Director 1970
Mr. Vincent J. Capponi M.S., MS Pres & COO 1958
Ms. Kathleen P. Bloch CPA, CPA, M.B.A., MBA CFO & Sec. 1955
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. Chief Medical Officer 1969
Ms. Terri Anne Powers M.B.A. VP of Investor Relations & Corp. Communications NA
Dr. Christian Steiner M.D. Exec. VP of Sales & Marketing NA
Mr. Christopher Cramer MBA, MS VP of Bus. Devel. NA
Dr. Robert H. Bartlett M.D. Co-Chairman of Cardiac Surgery Advisory Board & Consultant 1939
Mr. Vincent J. Capponi M.S. President & COO 1958
Ms. Kathleen P. Bloch CPA, M.B.A. Chief Financial Officer 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…